Combined Hepatocellular-cholangiocarcinoma, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Primary Liver Cancer
Conditions
Keywords
Next Generation Sequencing (NGS), Liquid biopsy, Immune Checkpoint Inhibitor, Whole Transcriptome Sequencing
Brief summary
To evaluate the predictive value of ctDNA in response, relapse for liver cancer patients treated with immune checkpoint inhibitors
Detailed description
In the study, 300 advanced primery liver cancer patients who received immune checkpoint inhibitors at first-line setting (N=200) or second-line setting (N=100) will be recruited. By analyzing the ctDNA and peripheral blood mononuclear cell (PBMC) collected before and after the first cycle of ICI treatment, the dynamic changes of bTMB, ctDNA and the composition of immune cells will be detected. Combined with the tumor markers AFP, DCP and CA19-9, a noninvasive multiparameter model will be developed.
Interventions
OTHERObservation
observe the association of ctDNA with efficacy of treatment
Sponsors
Eastern Hepatobiliary Surgery Hospital
Geneplus-Beijing Co. Ltd.
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Primary liver cancer diagnosed according to the clinical diagnostic criteria, or histopathological or cytological examination; * 18-80 years old, no limit on gender; * ECOG performance status of 0-2, with expected survival time of more than 12 weeks; * According to RECIST V1.1, there must be at least one measurable lesion; * Patients who are suitable for ICIs treatment and willing to comply with required protocols and give permission to use the data for clinical research and products development; * Patients who join the study voluntarily, sign a consent form, have good compliance, and comply with follow-up.
Exclusion criteria
* Patients with other primary cancers; * Patients with a severe parenchymal disease and unable to accept ICIs treatment; * Patients with a psychiatric disorder and unable to comply with this study; * Patients with symptomatic brain metastasis, anticipated complications or cognitive disorders that are associated with brain metastasis; * Adverse events related to prior anti-tumor treatment (except for hair loss of any grade) did not return to grade 1 or better; * History of cells or organ transplantation; * History of hypersensitivity to the drug administered in this study or contrast media for CT and MRI; * Patients who accepted hepatic local therapy (including ablation therapy, percutaneous injection of ethanol or acetic acid (PEI/PAI), high-intensity focused ultrasound (HIFU), transarterial chemoembolization (TACE)) within 14 days prior to initiation of the study; * Other reasons that the researchers think not suitable for ICIs treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PFS: Progression-free survival | 24 months | The time length from the date of randomization to any of the following events: disease progression or death from any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ORR: Objective Response Rate | 24 months | The proportion of patients with complete response or partial response. |
| OS: Overall Survival | 24 months | The time length from the date of randomization to the date of death. |
| TTD: Time to Treatment Discontinuation | 24 months | The time length from the date of randomization to the date of treatment discontinuation. |
Countries
China
Outcome results
None listed